Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 49.80% per year. The lowest was -69.90% per year. And the median was 21.15% per year.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Santhera Pharmaceuticals Holding AG 3-Year FCF Growth Rate Related Terms
XSWX:SANN vs VRTX, REGN, MRNA: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate falls into.
Santhera Pharmaceuticals Holding AG 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 21.60% mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a 3-Year FCF Growth Rate of 21.60% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Santhera Pharmaceuticals Holding AG and its competitors. This is near median its historical median of 21.15. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #514 out of 1108 companies in the Biotechnology industry, placing it in the top 46.4%.
Is Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate too high?
Santhera Pharmaceuticals Holding AG's current 3-Year FCF Growth Rate of 21.60% is near median its 10-year median of 21.15. The Biotechnology industry median 3-Year FCF Growth Rate is 19.25. Santhera Pharmaceuticals Holding AG's value of 21.60% is 12.2% above this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #514 out of 1108 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #514 out of 1108 companies for 3-Year FCF Growth Rate. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 19.25. Santhera Pharmaceuticals Holding AG's value of 21.60% is 12.2% above this benchmark. While the company's 10-year median is 21.15 vs. the industry median of 19.25, Santhera Pharmaceuticals Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.25, based on 1,108 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current 3-Year FCF Growth Rate of 21.60% is 12.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current 3-Year FCF Growth Rate is 21.60%, which is near median its own 10-year median of 21.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.95, compared to a current price of CHF14.92 — trading 37.7% below its estimated fair value. The current 3-Year FCF Growth Rate is 21.60%, which is near median its 10-year median of 21.15 and 12.2% above the Biotechnology industry median of 19.25. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current 3-Year FCF Growth Rate is 21.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF14.92 is trading 37.7% below its estimated GF Value™ of CHF23.95.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
3-Year FCF Growth Rate: 21.60% (near median its 10-year median of 21.15)
GF Value™: CHF23.95 vs. price of CHF14.92 (37.7% below fair value)
Industry Position: 12.2% above the Biotechnology median (#514 of 1108)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
30GF Score
Get the complete analysis for XSWX:SANN
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
